These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 31237444)

  • 1. Bladder cancer mortality after a diagnosis of nonmuscle-invasive bladder carcinoma.
    Abdel-Rahman O
    Future Oncol; 2019 Jul; 15(19):2267-2275. PubMed ID: 31237444
    [No Abstract]   [Full Text] [Related]  

  • 2. Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in a United States Population.
    Ravvaz K; Walz ME; Weissert JA; Downs TM
    J Urol; 2017 Oct; 198(4):824-831. PubMed ID: 28433642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review.
    Rouprêt M; Seisen T; Compérat E; Larré S; Mazerolles C; Gobet F; Fetissof F; Fromont G; Safsaf A; d'Arcier BF; Celhay O; Validire P; Rozet F; Irani J; Soulié M; Pfister C;
    J Urol; 2013 Jun; 189(6):2069-76. PubMed ID: 23201497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression.
    Yim MS; Ha YS; Kim IY; Yun SJ; Choi YH; Kim WJ
    J Urol; 2011 Feb; 185(2):701-5. PubMed ID: 21168882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer.
    Sonpavde G; Khan MM; Lerner SP; Svatek RS; Novara G; Karakiewicz PI; Skinner E; Tilki D; Kassouf W; Fradet Y; Dinney CP; Fritsche HM; Izawa JI; Bastian PJ; Ficarra V; Schoenberg M; Sagalowsky AI; Lotan Y; Shariat SF
    J Urol; 2011 Feb; 185(2):456-61. PubMed ID: 21167527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
    Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
    Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer.
    Sanchez A; Wszolek MF; Niemierko A; Clayman RH; Drumm M; Rodríguez D; Feldman AS; Dahl DM; Heney NM; Shipley WU; Zietman AL; Efstathiou JA
    J Urol; 2018 Feb; 199(2):407-415. PubMed ID: 28870862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Robot-Assisted Radical Cystectomy for Bladder Cancer in Octogenarians.
    De Groote R; Gandaglia G; Geurts N; Goossens M; Pauwels E; D'Hondt F; Gratzke C; Fossati N; De Naeyer G; Schatteman P; Carpentier P; Novara G; Mottrie A
    J Endourol; 2016 Jul; 30(7):792-8. PubMed ID: 26914490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer.
    Ayari C; LaRue H; Hovington H; Caron A; Bergeron A; Têtu B; Fradet V; Fradet Y
    Hum Pathol; 2013 Aug; 44(8):1630-7. PubMed ID: 23574787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
    Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
    Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant seminal vesicle invasion in pT4a urothelial carcinoma of the bladder with contiguous prostatic infiltration is an adverse prognosticator for cancer-specific survival after radical cystectomy.
    May M; Brookman-May S; Burger M; Gilfrich C; Fritsche HM; Rink M; Chun F; Fisch M; Roghmann F; Noldus J; Mayr R; Pycha A; Novotny V; Wirth M; Vallo S; Haferkamp A; Roigas J; Brisuda A; Stredele R; Volkmer B; Dechet C; Schnabel M; Denzinger S; Stief CG; Bastian PJ; Aziz A
    Ann Surg Oncol; 2014 Nov; 21(12):4034-40. PubMed ID: 24895114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of low- versus high-intensity surveillance cystoscopy on surgical care and cancer outcomes in patients with high-risk non-muscle-invasive bladder cancer (NMIBC).
    Rezaee ME; Lynch KE; Li Z; MacKenzie TA; Seigne JD; Robertson DJ; Sirovich B; Goodney PP; Schroeck FR
    PLoS One; 2020; 15(3):e0230417. PubMed ID: 32203532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma.
    Rieken M; Xylinas E; Kluth L; Crivelli JJ; Chrystal J; Faison T; Lotan Y; Karakiewicz PI; Sun M; Fajkovic H; Babjuk M; Bachmann A; Scherr DS; Shariat SF
    Urol Oncol; 2014 Jan; 32(1):49.e7-14. PubMed ID: 24140245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor.
    Kang M; Jeong CW; Kwak C; Kim HH; Ku JH
    Oncotarget; 2017 Feb; 8(8):12891-12901. PubMed ID: 28039452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival.
    Dotan ZA; Kavanagh K; Yossepowitch O; Kaag M; Olgac S; Donat M; Herr HW
    J Urol; 2007 Dec; 178(6):2308-12; discussion 2313. PubMed ID: 17936804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer.
    Cahn DB; Handorf EA; Ghiraldi EM; Ristau BT; Geynisman DM; Churilla TM; Horwitz EM; Sobczak ML; Chen DYT; Viterbo R; Greenberg RE; Kutikov A; Uzzo RG; Smaldone MC
    Cancer; 2017 Nov; 123(22):4337-4345. PubMed ID: 28743162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer.
    Clark PE; Stein JP; Groshen SG; Miranda G; Cai J; Lieskovsky G; Skinner DG
    J Urol; 2004 Oct; 172(4 Pt 1):1342-7. PubMed ID: 15371837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.